Clinical phenotype, atrophy, and small vessel disease in APOE ε2 carriers with Alzheimer disease
Authors:
- Colin GrootCGColin Groot
- Carole H. SudreCSCarole H. Sudre
- Frederik BarkhofFBFrederik Barkhof
- Charlotte E. TeunissenCTCharlotte E. Teunissen
- Bart N.M. van BerckelBBBart N.M. van Berckel
- Sang Won SeoSSSang Won Seo
- Sébastien OurselinSOSébastien Ourselin
- Philip ScheltensPSPhilip Scheltens
- M. Jorge CardosoMCM. Jorge Cardoso
- Wiesje M. van der FlierWFWiesje M. van der Flier
- Rik OssenkoppeleRORik Ossenkoppele
- 13 November 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 91 (20) , e1851-e1859
Abstract
Objective To examine the clinical phenotype, gray matter atrophy patterns, and small vessel disease in patients who developed prodromal or probable Alzheimer disease dementia, despite carrying the protective APOEε2 allele. Methods We included 36 β-amyloid-positive (by CSF or PET) APOEε2 carriers (all ε2/ε3) with mild cognitive impairment or dementia due to Alzheimer disease who were matched for age and diagnosis (ratio 1:2) to APOEε3 homozygotes and APOEε4 carriers (70% ε3/ε4 and 30% ε4/ε4). We assessed neuropsychological performance across 4 cognitive domains (memory, attention, executive, and language functions), performed voxelwise and region of interest analyses of gray matter atrophy on T1-weighted MRI, used fluid-attenuated inversion recovery images to automatically quantify white matter hyperintensity volumes, and assessed T2*-weighted images to identify microbleeds. Differences in cognitive domain scores, atrophy, and white matter hyperintensities between ε2 carriers, ε3 homozygotes, and ε4 carriers were assessed using analysis of variance analyses, and Pearson χ2 tests were used to examine differences in prevalence of microbleeds. Results We found that ε2 carriers performed worse on nonmemory domains compared to both ε3 homozygotes and ε4 carriers but better on memory compared to ε4 carriers. Voxelwise T1-weighted MRI analyses showed asymmetric (left > right) temporoparietal-predominant atrophy with subtly less involvement of medial–temporal structures in ε2 carriers compared to ε4 carriers. Finally, ε2 carriers had larger total white matter hyperintensity volumes compared to ε4 carriers (mean 10.4 vs 7.3 mL) and a higher prevalence of microbleeds compared to ε3 homozygotes (37.5% vs 18.3%). Conclusion APOEε2 carriers who develop Alzheimer disease despite carrying the protective allele display a nonamnestic clinical phenotype with more severe small vessel disease.Keywords
This publication has 48 references indexed in Scilit:
- Dissecting the Gene Dose-Effects of the APOE ε4 and ε2 Alleles on Hippocampal Volumes in Aging and Alzheimer’s DiseasePLOS ONE, 2013
- Classification of primary progressive aphasia and its variantsNeurology, 2011
- Hippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjectsNeurology, 2010
- Variants at APOE influence risk of deep and lobar intracerebral hemorrhageAnnals of Neurology, 2010
- Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyNature Reviews Neuroscience, 2009
- Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene databaseNature Genetics, 2007
- The apolipoprotein E varepsilon2 allele and decline in episodic memoryJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Protective effect of apoE ∈2 in Alzheimer's diseaseThe Lancet, 1994
- Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer diseaseNature Genetics, 1994
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991